- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT02120521
Serum STREM and MNDA Mointoring in ICU
The Predictive Values of Serum STREM and Its Correlation With MNDA Monitoring in Critically Ill Patients.
Přehled studie
Postavení
Podmínky
Detailní popis
A total of 120 patients will be included in the study. Sixty patients are critically ill with evidence of sepsis during ICU stay (sepsis group) and sixty patients are critically ill without evidence of infectious organism (SIRS group). At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum level of sTREM-1 and MNDA will be monitored.
At admission, patient's age, sex, weight and height were Patients data that include the clinical status; sequential organ failure assessment (SOFA) score; temperature; heart rate; respiratory rate; blood pressure; central venous pressure; laboratory analysis (complete blood count, blood urea nitrogen, blood sugar, serum sodium, potassium, calcium, aspartate aminotransferase, alanine aminotransferase, prothrombin time, albumin and CRP) and arterial blood gas analysis were measured. Routine cultures of suspected sites, blood and urine were obtained to determine the presence of infection. We attempted to maintain the patient hemoglobin level at 10-12g/dl and central venous pressure at 8-12 cmH2o. When needed, intravascular fluid replacement, blood products and inotropic or vasopressor agents were administered. Each day the attending physician evaluated all the study patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU.
The signs of sepsis were body temperature <36C° or > 38C°, tachycardia (>90 beats/min), ventilatory frequency>20 breath/min or Pco2<32mmHg (unless the patient was mechanically ventilated), a white cell count ≥12×109 litre-1 or < 4x 109 litre-1, or >10% immature neutrophils, in addition to the presence of infection. Severe sepsis is a sepsis associated with evidence of organ dysfunction , hypoperfusion, acute alteration of mental status, elevated plasma lactate, unexplained metabolic acidosis (arterial ph<7.3), hypoxaemia, prolonged prothrombin time or decrease in platelet count >50% or ≤100×109litre1, oliguria and hypotension defined as systolic arterial pressure <90mmHg or a decrease of >40mmHg. Septic shock was defined as hypotension (<90/60mmHg) in addition to sepsis syndrome persisting despite adequate fluid resuscitation and requiring intropic support
Typ studie
Zápis (Aktuální)
Kontakty a umístění
Studijní místa
-
-
Algharbyia
-
Tanta, Algharbyia, Egypt, 35217
- Tanta University Hospitals
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Popis
Inclusion Criteria:
- The patients staying in ICU for more than 24 hours will be included in the study.
Exclusion Criteria:
- Patients received anti-inflammatory drugs or corticosteroids before admission, patients had immunosuppressive illness, patients had chronic organ failure; patients received massive blood transfusion; patients with radiation therapy and patients with previous organ transplantation will be excluded from the study.
Studijní plán
Jak je studie koncipována?
Detaily designu
Kohorty a intervence
Skupina / kohorta |
---|
Sepsis group
Sixty patients are critically ill with evidence of sepsis during ICU stay (sepsis group) and sixty patients are critically ill without evidence of infectious organism (SIRS group).
At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured.
Routine cultures will be obtained.
The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU.
A serum level of sTREM-1 and MNDA will be monitored.
|
SIRS group
Sixty patients are critically ill without evidence of infectious organism (SIRS group).
At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured.
Routine cultures will be obtained.
The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU.
A serum level of sTREM-1 and MNDA will be monitored.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
dynamic changes of serum sTREM-1 and MNDA
Časové okno: one week
|
determine the dynamic changes of serum sTREM-1 and the corresponding changes of serum MNDA and their correlation in critically ill sepsis and SIRS patients.
|
one week
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Survival in critically ill sepsis and SIRS patients
Časové okno: two weeks
|
determine the dynamic changes of serum sTREM-1 and the corresponding changes of serum MNDA and their correlation in critically ill sepsis and SIRS patients and survival .
|
two weeks
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Ayman A Yousef, Assistant Professor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 1637/02/13
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Sepsis .
-
Drugs for Neglected DiseasesUniversiteit Antwerpen; PENTA Foundation; St George's, University of LondonDokončenoNovorozenecká SEPSISBangladéš, Uganda, Thajsko, Jižní Afrika, Itálie, Řecko, Indie, Brazílie, Čína, Keňa, Vietnam
-
Assiut UniversityNeznámýNovorozenecká SEPSIS
-
Assiut UniversityNeznámý
-
London School of Hygiene and Tropical MedicineDokončenoNovorozenecká SEPSISBurkina Faso, Gambie
-
Stephanie BjerrumRigshospitalet, Denmark; University of Copenhagen; University of Ghana; Korle-Bu...DokončenoNovorozenecká SEPSISGhana
-
Drugs for Neglected DiseasesUniversity of Oxford; KEMRI-Wellcome Trust Collaborative Research ProgramDokončenoNovorozenecká SEPSISKeňa
-
Gehad AbdelnaserAssiut UniversityNeznámý
-
Assiut UniversityNeznámý
-
Franciscus GasthuisErasmus Medical CenterDokončenoNovorozenecká infekce | Novorozenecká SEPSISHolandsko
-
Ahmed Mahmoud Ali Ali YoussefDokončenoNovorozenecká SEPSISEgypt